Region Ăstergötland Implements AI-Powered Stratipath Breast to Enhance Breast Cancer Diagnostics
Linköping University Hospital and Region Ăstergötland have chosen to implement Stratipath Breast as part of their clinical routine for early breast cancer diagnostics.
Region Uppsala chooses to implement AI-based risk profiling with Stratipath Breast
Region Uppsala, Swedenâs fourth largest healthcare region, has chosen to implement Stratipath Breast, an AI-based risk profiling solution for breast cancer, in clinical use.
Stratipath releases biopsy capability for its CE-IVD marked AI diagnostic solution, Stratipath Breast
Stratipath releases biopsy capability for its CE-IVD marked AI diagnostic solution, Stratipath Breast. The new capability strengthens clinical decision-making for neoadjuvant therapy.
Diagnexia and Stratipath Partner to Expand AI-Based Cancer Precision Diagnostics Across the UK and Europe
Diagnexia, and Stratipath AB are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.
Professor Daniel Hayes Joins Stratipathâs Scientific Advisory Board
Stratipath is proud to announce that globally recognized breast oncologist, Professor Daniel F. Hayes, has joined the companyâs Scientific Advisory Board. Professor Hayes will collaborate closely with the board, chaired by Professor Jonas Bergh, to further advance Stratipathâs innovative solutions in breast cancer precision diagnostics.
Unilabs is implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göranâs Hospital
Capio St Göranâs Hospital is one of the largest breast cancer clinics in Sweden treating more than 600 breast cancer patients annually. With this new collaboration, Unilabs will use Stratipath Breast on a selected group of these patients.
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
Stratipath is thrilled to announce a collaboration with Roche, the worldâs largest biotechnology company and the global leader in in-vitro diagnostics.
A new validation study on the prognostic performance of Stratipath Breast.
Stratipath is excited to announce the publication of a new validation study on the prognostic performance of Stratipath Breastâthe first AI-based CE-marked medical device for risk stratification of breast cancer using routine H&E histopathology images.
Stratipath Breast AI-based risk profiling for breast cancer is now available for clinical use in the UK.
Stratipath Breast, is now officially registered with the Medicines and Healthcare products Regulatory Agency (MHRA). This registration allows healthcare providers across the United Kingdom access to the AI-based prognostic tool for breast cancer risk profiling.
Stratipath is proud to be a part of Proscia’s new partner alliance âProscia Readyâ
Stratipath is proud to be a part of Proscia’s new partner alliance âProscia Readyâ.